Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis keeps hopes high for Prevacid 24HR

This article was originally published in The Tan Sheet

Executive Summary

Novartis expects the proton pump inhibitor to become a top-five OTC brand in the U.S. during its three-year market exclusivity, CEO Daniel Vasella says during an Oct. 22 third-quarter earnings call. The firm estimates Prevacid 24HR (lansoprazole) will hit 100,000 store shelves by mid-November (1"The Tan Sheet" Sept. 28, 2009, In Brief). Separately, Vasella said the firm's consumer business is benefiting as consumer spending picks up following a sluggish start this year. Specifically, the company's "good range" of cough and cold products for the current season drove sales of OTC drugs up 3 percent, he said. Consumer health business sales in the July-September period rose slightly to $1.5 billion. Overall net sales rose 3 percent to $11.1 billion, and net income was flat at $2.1 billion

You may also be interested in...



Prevacid 24HR Hits Shelves, Targets Rx-Users And Fed-Up Heartburn Sufferers

Novartis supports the Nov. 12 launch of over-the-counter proton pump inhibitor Prevacid 24HR with what the firm calls its "largest OTC product launch campaign to date.

OTC Prevacid poised for launch

An 1advertisement in the Oct. 23 issue of All You magazine says Novartis' Prevacid 24HR could be "available as early as November 12th." The Web site for the proton pump inhibitor, 2www.prevacid24hr.com, has been updated with additional information about the product, including packaging and drug facts. Novartis, which licenses Prevacid 24HR (lansoprazole 15 mg) from Takeda Pharmaceuticals, appears to position the drug as an alternative to prescription heartburn remedies, rather than attempting to draw away users of Procter & Gamble's Prilosec OTC (omeprazole 20 mg) - as the company said upon FDA approval of the switch in May (3"The Tan Sheet" May 18, 2009). The OTC PPI market may grow more crowded after December, when FDA's decision on Santarus/Schering-Plough's Zegerid (omeprazole 20 mg/sodium bicarbonate) is due (4"The Tan Sheet" June 29, 2009, In Brief)

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel